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INTRODUCTION {#sec1-1}
============

Acute respiratory infection is one of the leading causes of child and adult morbidity and mortality throughout the world \[Williams et al., [2002](#bib48){ref-type="ref"}\]. Determining the etiological diagnoses of patients who have respiratory symptoms remains a challenge both in the clinic and laboratory. Differentiating infections caused by influenza viruses from those caused by other respiratory viruses is essential for case management, as illustrated during the 2009 A/H1N1 influenza pandemic (A/H1N1p). Many definitions of influenza‐like illness (ILI) have been used worldwide in influenza surveillance; however, the sensitivity and positive predictive value of such definitions significantly vary depending on the co‐circulation of other respiratory viruses in the community \[Boivin et al., [2000](#bib7){ref-type="ref"}; Lee et al., [2011](#bib21){ref-type="ref"}; Thursky et al., [2003](#bib38){ref-type="ref"}\]. The identification of the respiratory viruses that are responsible for influenza‐like illness has been reported in many countries, and the percentage of positive swabs for at least one virus ranges from 32% to 65% \[Bellei et al., [2008](#bib5){ref-type="ref"}; Laguna‐Torres et al., [2009](#bib20){ref-type="ref"}; Ren et al., [2009](#bib33){ref-type="ref"}; Buecher et al., [2010](#bib8){ref-type="ref"}; Renois et al., [2010](#bib34){ref-type="ref"}; Razanajatovo et al., [2011](#bib32){ref-type="ref"}\]. Influenza‐like illness can be attributed to a wide range of respiratory viruses, including influenza viruses, adenoviruses (AdV), respiratory syncytial virus (RSV), enteroviruses (EVs), human rhinovirus (HRV), and parainfluenza viruses (PiVs) \[Bellei et al., [2008](#bib5){ref-type="ref"}; Laguna‐Torres et al., [2009](#bib20){ref-type="ref"}; Ren et al., [2009](#bib33){ref-type="ref"}; Buecher et al., [2010](#bib8){ref-type="ref"}; Renois et al., [2010](#bib34){ref-type="ref"}; Razanajatovo et al., [2011](#bib32){ref-type="ref"}\]. Recently, several viruses have been associated with respiratory infections, including human metapneumovirus (hMPV) \[van den Hoogen et al., [2001](#bib42){ref-type="ref"}\], human coronavirus NL63 (HCoV‐NL63) \[van der Hoek et al., [2004](#bib43){ref-type="ref"}\], human coronavirus HKU1 (HCoVHKU1) \[Woo et al., [2005](#bib49){ref-type="ref"}\], as well as human bocavirus (HBoV) \[Allander et al., [2005](#bib1){ref-type="ref"}\]. Three novel polyomaviruses, KIPyV, WUPyV, and MCPyV, have been detected recently in the respiratory tracts of humans; however, their pathogenicity remains controversial \[Norja et al., [2007](#bib28){ref-type="ref"}; Babakir‐Mina et al., [2011](#bib3){ref-type="ref"}\].

The 2009 A/H1N1p influenza pandemic provided a unique opportunity to investigate the distribution of different viruses in patients with influenza‐like illness in a large sample of the general population. Few studies have described epidemiological and clinical data for different respiratory viruses that were identified to be circulating during the A/H1N1p pandemic \[Hombrouck et al., [2011](#bib17){ref-type="ref"}; Lee et al., [2011](#bib21){ref-type="ref"}; Raboni et al., [2011](#bib31){ref-type="ref"}; Smit et al., [2011a](#bib35){ref-type="ref"}, [b](#bib36){ref-type="ref"}\]. This study describes the prevalence of 19 viruses in patients suspected with influenza by the general practitioner and then sent to a referral center for nasal swab sampling and subsequent laboratory testing during the A/H1N1p outbreak.

MATERIALS AND METHODS {#sec1-2}
=====================

Respiratory Specimens {#sec2-1}
---------------------

From June 2009 to January 2010, patients presenting with influenza‐like illness or suspected influenza were either referred to by their general practitioner, or consulted directly the doctor\'s group set up specifically for the management of suspect patients during the 2009 influenza pandemic at the Infectious Disease and Tropical Medicine Department of the North Hospital, Marseille, France.

Upon admission, patients were questioned and examined, and nasal swabs were collected and tested at the point‐of‐care (POC) laboratory by a rapid influenza diagnostic test (RIDT) and real‐time RT‐PCR (rRT‐PCR) \[Ninove et al., [2010](#bib26){ref-type="ref"}; Nougairede et al., [2010](#bib29){ref-type="ref"}\]. After obtaining oral consent, epidemiological and clinical questionnaires were completed while the patients waited for the RIDT result to be sent back by the POC lab. Patients with negative RIDT results returned home with isolation measures recommended until the result of the rRT‐PCR assay was obtained. When the rRT‐PCR results were obtained 12 hr later, patients with positive samples were contacted by telephone, and those with co‐morbidity risk factors were proposed for hospitalization, oseltamivir therapy, and isolation measures. For those without co‐morbidity risk factors, only symptomatic treatment was recommended.

Detection of Respiratory Viruses {#sec2-2}
--------------------------------

RIDT was performed using the Directigen EZ influenza A + B test (BD EZ Flu A + B, Becton, Dickinson) according to the manufacturer\'s instructions.

RNA extraction: 200 µl of the respiratory sample prepared for RIDT were spiked with 10 µl of in‐house MS2/T4 phages internal control \[Ninove et al., [2011](#bib27){ref-type="ref"}\]. RNA was extracted and eluted in 90 µl using the BioRobot EZ1 Workstation and the EZ1 Virus Mini Kit v2.0 (Qiagen, Courtaboeuf, France).

Reverse transcription was performed with the Taqman Reverse Transcription kit (Applied Biosystems, Branchburg, NJ) with 20 µl of RNA, 22 µl of MgCl~2~, 10 µl of 10× buffer, 20 µl of 10 mM dNTPs, 5 µl of hexamers (at 1/10 dilution), 2.5 µl of Multiscribe, and 2 µl of RNase inhibitor in a 100 µl final volume. The cycling program was 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min. For each sample, two reverse transcriptions in a 100 µl final volume were done, resulting in a 200 µl volume of cDNA to be used in PCR tests.

PCR assays were performed using the qPCR Mastermix‐No Rox kit (Eurogentec, Angers, France) with 10 µl of cDNA, 25 µl of Mastermix, 1 µl of each primer (10 mM), and 0.4 µl of probe (10 mM) in combination with a Stratagene MX3005P QPCR system (Agilent Technologies, La Jolla, CA). The primers and probes that were used in this study are listed in Table [I](#tbl1){ref-type="table"}. The cycling program was conducted at 50°C for 2 min, 95°C for 10 min, 45 cycles at 95°C for 15 sec, and 60°C for 60 sec.

###### 

References for the PCR That Were Used for the Detection of Respiratory Viruses

+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Viral etiology                         | Sequence of primers and probes                              | Protocol reference                      |                                                           |
+========================================+=============================================================+=========================================+===========================================================+
| Influenza virus A virus A/H1N1psw 2009 | GRswH1‐349F                                                 | GAGCTAAGAGAGCAATTGA                     | Duchamp et al. \[[2010](#bib13){ref-type="ref"}           |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| GRswH1‐601R                            | GTAGATGGATGGTGAATG                                          |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| GRswH1‐538Pr                           | FAM‐TTGCTGAGCTTTGGGTATGA--TAMRA                             |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Influenza virus A virus H3N2           | INFA‐23 F                                                   | CATYCTGTTGTATATGAGGCCCAT                | van Elden et al. \[[2001](#bib44){ref-type="ref"}         |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| INFA 1 R                               | GGACTGCAGCGTAGACGCTT                                        |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| INFA Pr                                | FAM‐CTCAGTTATTCTGCTGGTGCACTTGCCA‐TAMRA                      |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Rhinovirus                             | RHI2 F                                                      | C56 GCC 7GC GTG GC                      | Lu et al. \[[2008](#bib23){ref-type="ref"}                |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| RHI2 R                                 | GAA ACA CGG ACA CCC AAA GTA                                 |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| RHI2 Pr                                | FAM‐TCC TCC GGC CCC TGA ATG YGG C‐TAMRA                     |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Metapneumovirus                        | NLN‐F                                                       | CATATAAGCATGCTATATTAAAAGAGTCTC          | Mackay et al. \[[2003](#bib24){ref-type="ref"}            |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| NLN‐R                                  | CCTATTTCTGCAGCATATTTGTAATCAG                                |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| NLN‐Pr                                 | TGY AAT GAT GAG GGT GTC ACT GCG GTT G                       |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Respiratory syncytial virus A          | RSA 2bis F                                                  | GCA CAT CAT AAT TAG GAG TAT CAA T       | van Elden et al. \[[2003](#bib45){ref-type="ref"}         |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| RSA 1 R                                | AGA TCA ACT TCT GTC ATC CAG CAA                             |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| RSA Pr                                 | FAM CAC CAT CCA ACG GAG CAC AGG AGA T TAMRA                 |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Respiratory syncytial virus B          | RSB 2bis F                                                  | TGATATCCAGCATCTTTAAGTATCTTTATAGTG       | van Elden et al. \[[2003](#bib45){ref-type="ref"}         |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| RSB 1 R                                | AAG ATG CAA ATC ATA AAT TCA CAG GA                          |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| RSB Pr                                 | VIC AGG TAT GTT ATA TGC TAT GTC CAG GTT AGG AAG GGA A TAMRA |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Human coronavirus 229E                 | COR 229 E2 F                                                | AAA GGG CTA TAA AGA GAA TAA GGT ATT CT  | van Elden et al. \[[2004](#bib46){ref-type="ref"}         |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| COR 229 E1 R                           | CAG TCA AAT GGG CTG ATG CA                                  |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| COR 229 E Pr                           | CCC TGA CGA CCA CGT TGT GGT TCA                             |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Human coronavirus OC43                 | COR OC 43 1 F                                               | CGA TGA GGC TAT TCC GAC TAG GT          | van Elden et al. \[[2004](#bib46){ref-type="ref"}         |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| COR OC 43 2 R                          | CCT TCC TGA GCC TTC AAT ATA GTA ACC                         |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| COR OC 43 Pr                           | TCC GCC TGG CAC GGT ACT CCC T                               |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Human coronavirus NL63                 | hCoV‐NL63 F                                                 | CAG GGC TGA CAA GCC TTC TCA             | Tiveljung‐Lindell et al. \[[2009](#bib39){ref-type="ref"} |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| hCoV‐NL63                              | R GCA TCA ACA CCA TTC TGA ACA AGA                           |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| hCoV‐NL63 Pr                           | FAM‐CGT TGG AAG CGT GTT CCT ACC AGA GAG G‐TAMRA             |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Human coronavirus KU1                  | hCoV HKU‐1 F                                                | CAC TTC TAT TCC CTC CGA TGT TTC         | Tiveljung‐Lindell et al. \[[2009](#bib39){ref-type="ref"} |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| hCoV‐HKU‐1 R                           | TTA GAA GCA GAC CTT CCT GAG CC                              |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| hCoV‐HKU‐1 Pr                          | FAM‐CGC CTG GTA CGA TTT TGC CTC AAG GCT‐TAMRA               |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Enterovirus                            | EV 1 F                                                      | CCC CTG AAT GCG GCT AAT CC              | Watkins‐Riedel et al. \[[2002](#bib47){ref-type="ref"}    |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| EV 1 R                                 | ATT GTC ACC ATA AGC AGC CA                                  |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Ent TM 1 Pr                            | FAM CAN GGA CAC CCA AAG TAG TCG GTT CC TAMRA                |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Parechovirus                           | AN345 F                                                     | GTA ACA SWW GCC TCT GGG SCC AAA AG      | Benschop et al. \[[2008](#bib6){ref-type="ref"}           |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| AN344 R                                | GCC CCC WGR TCA GAT CCA YAG T                               |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| AN257 Pr                               | CCT RYG GGT ACC TYC WGG GCA TCC TTC                         |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Polyomavirus KI/KU                     | PyV2263F                                                    | TTGGATGAAAATGGCATTGG                    | Lindau et al. \[[2009](#bib22){ref-type="ref"}            |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PyV2404R                               | TAACCCTTCTTTGTCTAAARTGTAGCC                                 |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| KIPyV Pr                               | FAM‐ACATTACTTGTGCAGATATGCTTGGAACAGC‐TAMRA                   |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| WU PyV Pr                              | FAM‐CATAACTTGTGCTGACCTTTTGGGAGTTAAC‐TAMRA                   |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Parainfluenza virus 1/2/3/4            | PIV1 F                                                      | ACA GAT GAA ATT TTC AAG TGC TAC TTT AGT | Tong et al. \[[2008](#bib41){ref-type="ref"}              |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV1 R                                 | GCC TCT TTT AAT GCC ATA TTA TCA TTA GA                      |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV1 Pr                                | FAM‐ATG GTA ATA AAT CGA CTC GCT‐TAMRA                       |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV2 F                                 | TGC ATG TTT TAT AAC TAC TGA TCT TGC TAA                     |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV2 R                                 | GTT CGA GCA AAA TGG ATT ATG GT                              |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV2 Pr                                | FAM‐ACT GTC TTC AAT GGA GAT AT‐TAMRA                        |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV3 F                                 | TGC TGT TCG ATG CCA ACA A                                   |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV3 R                                 | ATT TTA TGC TCC TAT CTA GTG GAA GAC A                       |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV3 Pr                                | FAM‐TTG CTC TTG CTC CTC A‐TAMRA                             |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV4 F                                 | TGG CAA ATC GGC AAT TAA ACA                                 |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV4 R                                 | GGC TCT GGC AGC AAT CAT AAG                                 |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| PIV4 Pr                                | FAM‐TTC TGC ATT GAT GTG GCC TGT AAG GA‐TAMRA                |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Bocavirus                              | Boca NP1 F                                                  | AGA GGC TCG GGC TCA TAT CA              | Allander et al. \[[2007](#bib2){ref-type="ref"}           |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Boca NP1 R                             | CAC TTG GTC TGA GGT CTT CGA A                               |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Boca NP1 Pr                            | 6FAM AGG AAC ACC CAA TCA RCC ACC TAT CGT CT TAMRA           |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| Adenovirus                             | AQ1 F                                                       | GCC ACG GTG GGG TTT CTA AAC TT          | Heim et al. \[[2003](#bib15){ref-type="ref"}              |
|                                        |                                                             |                                         |                                                           |
|                                        |                                                             |                                         | \]                                                        |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| AQ2 R                                  | GCC CCA GTG GTC TTA CAT GCA CAT C                           |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+
| AP Pr                                  | FAM‐TGC ACC AGA CCC GGG CTC AGG TAC TCC GA‐TAMRA            |                                         |                                                           |
+----------------------------------------+-------------------------------------------------------------+-----------------------------------------+-----------------------------------------------------------+

Wiley Periodicals, Inc.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

Internal and External Controls {#sec2-3}
------------------------------

All steps (extraction, RT, PCR) were monitored with our universal internal control assay based on the use of DNA and RNA bacteriophages as described previously \[Ninove et al., [2011](#bib27){ref-type="ref"}\]. PCR detection of T4 and MS2 bacteriophages was performed in parallel with other PCR using the same cycling program in a 15‐µl final volume with 3 µl of cDNA, 7.5 µl of Mastermix, 0.3 µl of each primer (10 mM), and 0.15 µl of probe (10 mM). For each sample, the run was validated by the results that were obtained for T4 and MS2 \[Ninove et al., [2011](#bib27){ref-type="ref"}\].

Statistical Analyses {#sec2-4}
--------------------

The questionnaire was entered anonymously into the database with Epidata 3.1 (Centers for Disease Control and Prevention criteria for influenza‐like illness, CDC, Atlanta, GA), and data were analyzed with SPSS, version 19.0 (SPSS Inc., Chicago, IL). To identify the clinical characteristics of each group of patients, all potential variables were first assessed individually in a univariate model, and *P* values were measured for qualitative variables using Pearson\'s chi‐square test or Fisher\'s exact test and for continuous variables using the Mann--Whitney non‐parametric test. Correlations were assessed using the Spearman non‐parametric test. Variables with *P* values \<0.20 were retained and entered into a multivariate logistic regression analysis.

RESULTS {#sec1-3}
=======

During the 29 weeks of the outbreak, 660 patients were seen at the outpatient clinic. Two peaks of influenza‐like illness were detected, the first peak (181 patients) from week 36 to 41 (wave 1) and the second peak (256 patients) from week 43 to 48 (wave 2) (Fig. [1](#fig1){ref-type="fig"}). Among the 660 patients, 59.8% were female, more than half (53.9%) were between the ages of 20 and 40 and 6 (0.9%) were older than 65. The clinical characteristics and risk factors for serious illness are listed in Table [II](#tbl2){ref-type="table"}. The study was authorized by the ethics committee board of the university, number 10‐0010.

![Weekly distribution of viruses causing respiratory infections from June 2009 (week 25) to January 2010 (week 01--10) in Marseille, France. ADV, adenovirus; hCoV OC43, human coronavirus OC43; EV, enterovirus; hMPV, human metapneumovirus; HRV, rhinovirus; A/H1N1p, 2009 pandemic A/H1N1 influenza virus; PIV, parainfluenza virus. \[Color figure can be seen in the online version of this article, available at <http://wileyonlinelibrary.com/journal/jmv>\]](JMV-84-1071-g001){#fig1}

###### 

Comparative Clinical and Epidemiological Characteristics of all of the Patients Stratified by A/H1N1p and HRV Infection

                                Characteristics   N (%) total   N (%) A/H1N1p   N (%) HRV     A/H1N1p vs. non‐A/H1N1p   HRV vs. non‐HRV    A/H1N1p vs. HRV                                
  ----------------------------- ----------------- ------------- --------------- ------------- ------------------------- ------------------ ------------------ -------- ------------------ ------------------
  Sex                           Female            395 (59.8)    79 (50)         19 (32.8)     \<0.01                    1.7 (1.19; 2.44)   0.6                         \<0.05             0.5 (0.26; 0.92)
  Male                          265 (40.2)        79 (50)       39 (67.2)                                                                                                                 
  Age                           Mean (SD)         31 (14.27)    26.6 (12.12)    32.6 (12.7)   \<0.0001                                     0.8                         \<0.01             
  ≤10                           40 (6.1)          10 (6.4)      1 (1.7)         \<0.0001                                1.0                                   \<0.05                      
  11--20                        110 (16.7)        40 (25.5)     10 (17.2)                                                                                                                 
  21--30                        195 (29.5)        56 (35.7)     17 (29.3)                                                                                                                 
  31--40                        160 (24.2)        35 (22.3)     14 (24.1)                                                                                                                 
  41--50                        78 (11.8)         7 (4.5)       9 (15.5)                                                                                                                  
  51+                           76 (11.5)         9 (5.7)       7 (12.1)                                                                                                                  
  Clinical characteristics      Tp° mean (SD)     38.5 (0.90)   38.5 (0.95)     38.4 (0.79)   0.75                                         0.9                         0.5                
  Influenza‐like illness        358 (75.2)        141 (89.2)    43 (74.1)       \<0.001       2.8 (1.64; 4.85)          0.5                                   \<0.01   0.4 (0.16; 0.75)   
  Fever                         556 (84.9)        143 (90.5)    46 (79.3)       \<0.05        1.9 (1.08; 3.47)          0.5                                   \<0.05   0.4 (0.18; 0.92)   
  Cough                         545 (83.2)        153 (96.8)    50 (86.2)       \<0.0001      8.2 (3.28; 20.49)         0.5                                   \<0.01   0.2 (0.06; 0.65)   
  Sore throat                   424 (64.7)        103 (65.2)    40 (69)         0.9                                     0.4                                   0.6                         
  Asthenia                      611 (93.3)        151 (95.6)    51 (87.9)       0.2                                     0.3                                   0.06     0.3 (0.11; 1.01)   
  Myalgia                       521 (79.7)        126 (80.3)    43 (74.1)       0.8                                     0.5                                   0.3                         
  Rhinorrhea                    414 (63.2)        117 (74.1)    47 (81)         \<0.01        1.9 (1.29; 2.86)          \<0.001            3.3 (1.61; 6.62)   0.3                         
  Headache                      507 (77.4)        123 (77.8)    40 (69)         0.8                                     0.07               0.6 (0.29; 1.06)   0.2                         
  Chills                        427 (65.2)        117 (74.1)    30 (51.7)       \<0.01        1.7 (1.16; 2.57)          \<0.05             0.6 (0.31; 0.99)   \<0.01   0.4 (0.20; 0.70)   
  Arthralgia                    259 (39.7)        65 (41.4)     18 (31)         0.6                                     0.3                                   0.2                         
  Diarrhea                      109 (16.6)        29 (18.4)     7 (12.1)        0.5                                     0.5                                   0.3                         
  Nausea                        230 (35.2)        62 (39.2)     13 (22.8)       0.2                                     \<0.05             0.5 (0.24; 0.93)   \<0.05   0.5 (0.23; 0.92)   
  Vomiting                      104 (15.9)        35 (22.2)     8 (14)          \<0.05        1.8 (1.12; 2.77)          0.9                                   0.2                         
  Conjunctive hyperemia         66 (11.1)         23 (17.8)     6 (12)          \<0.01        2.1 (1.24; 3.71)          1.0                                   0.4                         
  Dyspnea                       160 (24.5)        54 (34.2)     15 (26.3)       \<0.01        1.9 (1.28; 2.82)          0.7                                   0.3                         
  Medical history/risk factor   Recent travel     106 (16.2)    18 (11.4)       8 (13.8)      0.06                      0.6 (0.35; 1.03)   0.6                         0.6                
  Live locally                  658 (99.7)        158 (100)     57 (98.3)       1.0                                     0.4                                   0.3                         
  Pregnant (2nd trimester)      36 (5.6)          6 (4)         7 (12.3)        0.3                                     0.06               2.7 (1.01; 7.41)   \<0.05   3.4 (1.08; 10.5)   
  Chronic bronchopathy          92 (14.4)         21 (14.1)     13 (22.8)       0.9                                     0.1                                   0.1                         
  Cardiopathy                   11 (1.7)          3 (2)         1 (1.8)         0.7                                     1.0                                   1.0                         
  Neurologic                    10 (1.6)          5 (3.4)       1 (1.8)         0.05          3.4 (0.97; 11.88)         0.4                                   1.0                         
  Hematologic                   7 (1.1)           2 (1.3)       0 (0)           0.7                                     0.6                                   1.0                         
  Metabolic                     38 (5.9)          12 (8.1)      2 (3.5)         0.2                                     0.7                                   0.4                         
  Immunodeficiency              11 (1.7)          2 (1.3)       2 (3.5)         1.0                                     0.3                                   0.3                         
  Obesity                       9 (1.4)           0 (0)         0 (0)           0.1                                     0.6                                                               
  Alcohol/hepatopathy           9 (1.4)           3 (2)         0 (0)           0.4                                     0.6                                   0.6                         
  \>65 Years old                6 (0.9)           1 (0.7)       0 (0)           1.0                                     0.6                                   1.0                         
  Risk factor (one or more)     189 (28.6)        44 (27.8)     21 (36.2)       0.8                                     0.6                                   0.2                         
  Hospitalization               22 (3.3)          5 (3.2)       2 (3.4)         0.9                                     0.7                                   1.0                         
  Total                         660               186           58                                                                                                                        

HRV, rhinovirus; A/H1N1p, 2009 pandemic A/H1N1 influenza virus.
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Virus Detection {#sec2-5}
---------------

Among the 660 patients, 158 were positive for A/H1N1p. Among the 502 patients with negative rRT‐PCR results for A/H1N1p, 286 samples (randomly chosen from the samples still available, 104 patients were seen during the wave 1, 123 patients were seen during the wave 2, and the remaining 59 patients during the other periods) were tested for 18 other respiratory viruses: 82 were positive for at least one virus (58 were positive for HRV, nine for HCoV OC43, five for EV, five for PIV1, one for PIV2, three for PIV4, four for AdV, and two for hMPV). The remaining 204 samples were found negative for all viruses tested in the study (Fig. [2](#fig2){ref-type="fig"}).

![Distribution of viruses that were diagnosed in patients who presented at the hospital influenza group and were tested for all 19 agents. ADV, adenovirus; hCoV OC43, human coronavirus OC43; EV, enterovirus; hMPV, human metapneumovirus; HRV, rhinovirus; A/H1N1p, 2009 pandemic A/H1N1 influenza virus; PIV, parainfluenza virus. \[Color figure can be seen in the online version of this article, available at <http://wileyonlinelibrary.com/journal/jmv>\]](JMV-84-1071-g002){#fig2}

During the first wave, 15 (8.3%) patients had positive swabs for A/H1N1p and among the 104 patients who were tested for other viruses, 25 (24%) had positive swabs for HRV and 72 (69%) had negative swabs. During the second wave, the percentage of patients who tested positive for A/H1N1p was significantly higher than that observed during the first wave (42.2%, *P* \< 0.001, OR = 8, and 95% CI: 4.5; 14.5), whereas, among the 123 patients who were tested for other viruses, HRV had a consistent prevalence (16.3%, *P* = 0.143). Among the 286 samples tested for other viruses, co‐infection was identified in five patients: one HRV with ADV, one HRV with PIV4, one EV with hCoV OC43, one hMpV with ADV, and one PIV with ADV. No patients with co‐infections were hospitalized.

Clinical Features {#sec2-6}
-----------------

Patient characteristics were stratified by infection status (Table [II](#tbl2){ref-type="table"}). In 75% of the cases, patients presented with an influenza‐like illness according to the definition proposed by the CDC with the following symptoms: a temperature \>37.8°C and either a cough or sore throat \[Babcock et al., [2006](#bib4){ref-type="ref"}; CDC, [2010](#bib11){ref-type="ref"}\]. Only three patients were asymptomatic. Among the influenza‐like illness patients, 100 (27.9%) were positive for A/H1N1p and 27 (18.1%), 6 (4%), 5 (3.4%), 3 (2.1%), and 1 (0.7%) of the tested patients, were positive for HRV, PIV (1, 2, or 4), hCoV OC43, ADV, and hMpV, respectively (Table [III](#tbl3){ref-type="table"}). Of all of the patients, 22 were hospitalized later, 5 (22.7%) had confirmed A/H1N1p infection, and 2 (9%) tested positive for HRV.

###### 

Etiologic Agent of Viral Respiratory Infection in Patients With or Without Influenza‐like Illness (According to the CDC\'s Definition) From June 2009 to January 2010 in Marseille, France

  Virus                                Clinical presentation   *P*‐value   
  ------------------------------------ ----------------------- ----------- -------
  A/H1N1p                              100 (27.9)              30 (25.4)   0.596
  EV                                   1 (0.3)                 1 (0.8)     0.406
  HRV                                  27 (7.5)                7 (5.9)     0.537
  hMPV                                 1 (0.3)                 0           0.565
  hCoV OC43                            5 (1.4)                 1 (0.8)     0.641
  PIV 1                                4 (1.1)                 1 (0.8)     0.803
  PIV 2                                0                       0           
  PIV 4                                2 (0.6)                 1 (0.8)     0.728
  AdV                                  3 (0.8)                 0           0.315
  Negative for all viruses tested      108 (30.2)              39 (33.1)   0.311
  Not tested for respiratory viruses   109 (30.4)              39 (33.1)   0.596
  Total                                358                     118         

ADV, adenovirus; hCoV OC43, human coronavirus OC43; EV, enterovirus; hMPV, human metapneumovirus; HRV, rhinovirus; A/H1N1p, 2009 pandemic A/H1N1 influenza virus; PIV, parainfluenza virus.
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Patients who tested positive for A/H1N1p were significantly younger (26.61 years with 95% CI: 24.70--28.52) than those who tested negative for A/H1N1p (32.28 years with 95% CI: 30.91--33.67; *P* = 0.0001). When analyzed by univariate analysis, cough (96.8%), self‐reported fever (90.5%), rhinorrhea (74%), chills (74%), vomiting (22.1%), conjunctive hyperemia (17.8%), and dyspnea (34.1%) were significantly more prevalent in A/H1N1p‐positive patients with odds ratios (OR) ranging from 1.72 to 8.20 (Table [II](#tbl2){ref-type="table"}). The presence of diarrhea was not associated significantly with A/H1N1p‐negative patients but was associated with traveling abroad, myalgia, nausea, and fever. Multivariate analyses demonstrated that cough (OR = 6.89 and 95% CI: 2.71--17.51; *P* \< 0.001), chills (OR = 1.63 and 95% CI: 1.03--2.57; *P* = 0.035), conjunctive hyperemia (OR 1.93 and 95% CI: 1.07--3.48; *P* = 0.028), and dyspnea (OR = 1.58 and 95% CI: 1.01--2.47; *P* = 0.044) were associated independently with A/H1N1p infection when compared with A/H1N1p‐negative patients.

Since HRV was the second virus detected most frequently in swab samples, A/H1N1p‐positive patients were compared also with those who were positive for HRV, using univariate analyses. Fever (*P* = 0.027), cough (*P* = 0.007), chills (*P* = 0.002), and nausea (*P* = 0.026) were more frequent in patients with A/H1N1p‐positive swabs. Patients with HRV‐positive swabs were older (32.6 vs. 26.6, *P* = 0.002) (Table [II](#tbl2){ref-type="table"}). Multivariate analyses identified that cough (OR = 5 and 95% CI: 1.32--19.01; *P* = 0.018) and chills (OR = 3.18 and 95% CI: 1.57--6.47; *P* = 0.001) were associated independently with A/H1N1p infection.

DISCUSSION {#sec1-4}
==========

In this prospective cohort, two waves of influenza‐like illness were observed in the epidemic curve. The first wave occurred in mid‐September, with a low prevalence of A/H1N1p (8.3%); in contrast with previously published data \[Casalegno et al., [2009a](#bib9){ref-type="ref"}, [b](#bib10){ref-type="ref"}\], HRV (24%) could not explain completely this wave, and the majority of the etiologic agents were not identified. The second wave occurred in mid‐November, corresponding to the highest prevalence of A/H1N1p (42.2%) while the other viruses (as HRV or PIVs) was observed with the same prevalence.

After A/H1N1p, HRV was detected most commonly in patients (20.3% of tested patients). These results are consistent with previous data, which suggest that HRV is one of the most frequent causes of acute respiratory infection in adults and children, with a prevalence ranging from 6% to more than 40% \[Bellei et al., [2008](#bib5){ref-type="ref"}; Ren et al., [2009](#bib33){ref-type="ref"}; Buecher et al., [2010](#bib8){ref-type="ref"}; Renois et al., [2010](#bib34){ref-type="ref"}; Razanajatovo et al., [2011](#bib32){ref-type="ref"}; Tokarz et al., [2011](#bib40){ref-type="ref"}\].

Among the different hCoVs that were tested, hCoV OC 43 was the only strain found in 9 of the 286 samples that were tested (3.1%). This prevalence is similar to other studies that report hCoV OC43 in nearly 2% of patient samples \[Bellei et al., [2008](#bib5){ref-type="ref"}; Ren et al., [2009](#bib33){ref-type="ref"}; Renois et al., [2010](#bib34){ref-type="ref"}\].

Nine patients were positive for at least one of the PiVs. Although PIV1, PIV2, and PIV3 are considered to be the most frequently identified PIVs \[Henrickson, [2003](#bib16){ref-type="ref"}\], PIV1, and PIV4 were detected primarily, which is similar to the findings of Renois et al. \[[2010](#bib34){ref-type="ref"}\]. The lack of PIV3 detection may be due to the virus being commonly identified only during the first year of life \[Renois et al., [2010](#bib34){ref-type="ref"}\].

The real‐time PCR method used for the diagnosis of EV was designed most specifically for diagnostics of central nervous system infections; however, recent studies have used a generic pan‐EV/rhinovirus real‐time PCR and have identified a novel respiratory EV that could not be detected by the systems designed for meningitis diagnostics \[Watkins‐Riedel et al., [2002](#bib47){ref-type="ref"}; Tapparel et al., [2009](#bib37){ref-type="ref"}\]. Although it is possible that some EVs remained undetected, five samples were tested positive for EVs (1.7% of tested patients), which is consistent with previous studies in patients with acute respiratory infection or influenza‐like illness \[Bellei et al., [2008](#bib5){ref-type="ref"}; Laguna‐Torres et al., [2009](#bib20){ref-type="ref"}; Ren et al., [2009](#bib33){ref-type="ref"}\].

In this study, four samples (1.4%) were positive for AdV and two samples (0.7%) were positive for hMpV. These prevalences are comparable with previous reports \[Bellei et al., [2008](#bib5){ref-type="ref"}; Laguna‐Torres et al., [2009](#bib20){ref-type="ref"}; Ren et al., [2009](#bib33){ref-type="ref"}\].

The absence of RSV infection could be explained by the mean age (31 year old) of the tested population, and by the delayed epidemic of RSV infection in France during the 2009--2010 winter season \[Casalegno et al., [2009a](#bib9){ref-type="ref"}, [b](#bib10){ref-type="ref"}\].

The clinical significance of co‐infections is unclear \[Jartti et al., [2004](#bib18){ref-type="ref"}\]. In this study, only 5 of the 286 tested swabs (1.7%) were positive for more than one respiratory virus, which was lower than previously reported \[Esper et al., [2011](#bib14){ref-type="ref"}; Hombrouck et al., [2011](#bib17){ref-type="ref"}; Raboni et al., [2011](#bib31){ref-type="ref"}; Tokarz et al., [2011](#bib40){ref-type="ref"}\], whereas this result is biased by the fact that only the patients who were negative for A/H1N1p were tested for the other viruses.

During the A/H1N1p pandemic, circulation of influenza B and A/H3N2 was null and very limited, respectively \[Renois et al., [2010](#bib34){ref-type="ref"}; Nakamura et al., [2011](#bib25){ref-type="ref"}; Tokarz et al., [2011](#bib40){ref-type="ref"}\]. Therefore, patients who had negative RIDT results were not tested for influenza B.

There are multiple clinical definitions of influenza‐like illness. None are satisfactorily sensitive and specific for defining influenza virus infection \[Thursky et al., [2003](#bib38){ref-type="ref"}; CDC, [2010](#bib11){ref-type="ref"}\]. Although 75% of the clinical presentations were defined as influenza‐like illness according to the CDC definition \[CDC, [2010](#bib11){ref-type="ref"}\], only 28% were confirmed influenza by laboratory documentation. Moreover, the percentage of patients with A/H1N1p‐positive swabs did not differ significantly between patients with symptoms of influenza‐like illness and those who did not present with these symptoms. Patients with influenza‐like illness also had swabs that tested positive for HRV, EV, hMpV, ADV, PIVS, or hCoV OC43. The clinical characteristics of patients with A/H1N1p infection have been reported in several countries \[Crum‐Cianflone et al., [2009](#bib12){ref-type="ref"}; Ong et al., [2009](#bib30){ref-type="ref"}; Kim et al., [2010](#bib19){ref-type="ref"}; Hombrouck et al., [2011](#bib17){ref-type="ref"}; Lee et al., [2011](#bib21){ref-type="ref"}; Smit et al., [2011a](#bib35){ref-type="ref"}, [b](#bib36){ref-type="ref"}\]. Of these eight studies, the clinical features that were associated mostly with A/H1N1p were the cough and the fever.

Several studies have reported the results from respiratory virus testing using respiratory samples that were obtained from patients with influenza‐like illness or acute respiratory infection throughout the world and during different times. Although the target populations, inclusion criteria, seasonality, climate, environment, diagnostic methods, and numbers of viruses or bacteria that were tested differed, the proportion of non‐documented cases remained relatively high \[Bellei et al., [2008](#bib5){ref-type="ref"}; Laguna‐Torres et al., [2009](#bib20){ref-type="ref"}; Renois et al., [2010](#bib34){ref-type="ref"}\].

In conclusion, this study found (i) that many respiratory viruses circulated during the A/H1N1p pandemic in France, (ii) that A/H1N1p virus circulation did not impact on the kinetics of other respiratory viruses, (iii) that the percentage of non‐documented cases remains high and therefore justify to pursue technical development and to enlarge the variety of microorganisms in detection panels, (iv) that CDC definition of influenza‐like illness symptoms are not capable to distinguish A/H1N1p virus from other respiratory viruses, and finally, and (v) that the most specific criteria in favor of A/H1N1p infection was cough.

Systematic testing for respiratory viruses is necessary to improve the targeting of appropriate antiviral treatments. Specific studies exploring (i) the prevalence of co‐infections and their clinical characteristics, (ii) socio‐economic consequences of the different microorganisms involves in respiratory infections not only at the hospital level but more broadly inside and outside of the hospital are necessary for a better management of cases.
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